Visão geral da empresa
A clinical-stage biopharmaceutical entity, Omeros Corporation is dedicated to the discovery, development, and commercialization of small-molecule and protein therapeutics, with a specific focus on orphan indications that target immunologic diseases. The company operates within the broader healthcare sector and specifically within the biotechnology industry, a classification that defines its engagement in high-risk, high-reward research aimed at advancing medical treatments for rare or specialized conditions. Currently, the organization employs a workforce of 175 individuals and maintains a market capitalization of $828.68M, though its annual revenue figures are not disclosed in the available financial data. This market capitalization of $828.68M indicates a mid-cap positioning within the biotechnology landscape, suggesting the company has established a significant presence yet remains subject to the volatility typical of early-stage development phases where revenue generation is still being scaled or optimized.
Saúde financeira
The financial performance of Omeros Corporation is characterized by a reported net income of $-4,808,000 and an EBITDA of $-121,832,000, while specific revenue figures are not available for the trailing twelve months. The substantial gap between the reported net income of $-4,808,000 and the significantly larger EBITDA loss of $-121,832,000 reveals a cost structure heavily influenced by non-operating expenses, such as interest costs or other financial charges that depress net income far below the operational earnings before interest and taxes. Despite these operating losses, the company demonstrates notable financial flexibility with a free cash flow of $170.34M and a cash balance of $171.80M, which provides a robust buffer to fund ongoing research and development activities without immediate reliance on external financing. The company's profitability margins reflect its clinical-stage status, showing a gross margin of 0.0%, an operating margin of 0.0%, and a profit margin of 0.0%, all of which indicate that the business is currently in an investment phase where revenue generation does not yet cover direct or indirect costs on a profitable basis. On the liability side, the firm holds $171.80M in cash against total debt of $249.84M, and while the debt-to-equity ratio is not applicable, the negative price-to-book ratio of -6.81 suggests the company's assets are valued below its market price on a book value basis. Liquidity is supported by a current ratio of 2.76, which indicates a strong ability to meet short-term obligations with its current assets. Return metrics further illustrate the financial reality of a growth-stage firm, with a return on assets of -25.5% and a return on equity that is not applicable due to the capital structure or negative equity position, signaling that management effectiveness in generating returns is currently constrained by the high capital intensity required for biotechnological innovation.
Avaliação de valorização
Valuation metrics for Omeros Corporation present a complex picture, with a trailing twelve-month P/E ratio that is not applicable and a forward P/E of 8.36, implying that the market expects future earnings growth to eventually materialize and justify the current stock price. The price-to-book ratio stands at -6.81, a figure that indicates the market is pricing the company significantly below its book value, a common scenario for biotechnology firms where intangible assets like intellectual property are not fully captured on the balance sheet. Since the price-to-sales ratio is not available, the valuation is largely assessed through alternative metrics such as the EV/EBITDA of -7.44, which suggests the enterprise value is negative relative to earnings before interest, taxes, depreciation, and amortization, reflecting the company's net cash position and lack of current profitability. The stock has exhibited significant volatility over the past year, trading between a 52-week high of $17.65 and a 52-week low of $2.95, with the current price position relative to this range indicating potential for substantial upside or downside depending on clinical trial outcomes and market sentiment. The beta value of 2.53 confirms that the stock's price volatility is more than double that of the broader market, highlighting the high-risk nature of investing in a clinical-stage biopharmaceutical company where price swings are driven by binary events like regulatory approvals or trial results.
Growth & Income
Growth metrics for Omeros Corporation are currently unavailable for the trailing twelve months, and earnings growth rates are also not disclosed, which means the trajectory of earnings relative to revenue cannot be quantified at this specific point in time. The company does not pay dividends, evidenced by a dividend yield that is not applicable and a payout ratio of 0.0%, indicating that the firm retains all its earnings and cash flow to reinvest directly into research, development, and commercialization efforts rather than distributing income to shareholders. This reinvestment strategy is typical for clinical-stage biopharmaceutical companies that prioritize accelerating product pipelines and bringing therapies to market over providing immediate income returns to investors. Consequently, the overall growth and income profile of Omeros Corporation is defined by its focus on capital appreciation through future product approvals and market expansion, rather than current dividend income or established revenue growth rates.